![]() |
|
|
Department of Molecular Biosciences, School of Veterinary Medicine, University of California, Davis, CA 95616
This study was conducted to determine the effect of excess leucine on the dietary choice of kittens. The basal diets contained 16% (low nitrogen) or 24% (adequate nitrogen) amino acids and were limiting in isoleucine and valine. The addition of leucine to either of these basal diets has been shown to cause a transitory adverse effect on the growth and food intake of kittens. In separate experiments each basal diet was used to test three sets of choices: basal vs. basal + 10% leucine; basal + alanine vs. basal + leucine (isonitrogenous) and basal vs. basal + alanine. When offered basal vs. basal + excess leucine, the kittens chose significantly more of the excess leucine diet regardless of the level of nitrogen in the basal diet. When offered an isonitrogenous choice of excess alanine vs. excess leucine, the kittens selected somewhat more of the excess leucine diets over the excess alanine diets; this selection was sustained longer in kittens fed low nitrogen. In the third choice experiment (basal vs. basal + alanine), the group offered the low nitrogen diets exhibited no preferences, and the group offered adequate-nitrogen diets selected significantly more of the excess alanine diet. These results for kittens are opposite to those for rats, a species that will select a low protein basal or even a protein-free diet over a diet containing excess leucine.
KEY WORDS: branched-chain amino acids kittens leucine dietary choice
1 Supported in part by a grant from the Pet Food Institute.
2 Part of this research was presented as an abstract: Hargrove, D. M., Rogers, Q. R., & Morris, J. G. (1985). Effect of excess leucine on dietary choice of the cat, a mammalian carnivore. The Book of Abstracts, XIII International Congress of Nutrition, Brighton, U.K., p. 60.
3 The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 USC section 1734 solely to indicate this fact.
4 Current address: Pfizer Central Research, Eastern Point Road, Groton, CT 06340.
5 To whom correspondence should be addressed.
Manuscript received 14 August 1993. Revision accepted 9 December 1993.